A Missouri woman has filed a federal lawsuit alleging that a Nevro spinal cord stimulation device implanted to treat chronic ...

HFX AdaptivAI combines insights from over 100,000 patients and more than 100 million data points¹ and leverages artificial intelligence (AI) to deliver responsive and personalized pain relief in real ...

Publications Show Reductions in Hospital Resource Utilization Associated with 10 kHz Therapy Spinal Cord Stimulation for the Treatment of Painful Diabetic Neuropathy and Nonsurgical Refractory Back ...

Data Published in Journal of Neurosurgery: Spine Highlight Lasting Pain Relief, Enhanced Function, Quality of Life, and Reduced Opioid Dependency with High-Frequency SCS Therapy The published 24-month ...

Nevro Corp ( (NVRO)) just unveiled an announcement. Nevro Corp. reported a better-than-expected worldwide revenue and adjusted EBITDA for Q3 2024, despite a 6.7% decline in overall revenue due to ...

Nevro is bringing artificial intelligence to its spinal cord stimulation solutions. The Redwood City, CA-based company said it won FDA approval for the HFX iQ with HFX AdaptivAI - a responsive, ...

Backed by the likes of Johnson & Johnson and Mayo Clinic, Nevro Corp. has raised $58 million to prepare for a hoped-for U.S. launch of its spinal cord stimulator for chronic pain, according to a ...

The two companies have been clashing over intellectual property since shortly after Nevro's Senza spinal cord stimulation system was approved by FDA last year. Jamie Hartford Nevro's Senza system ...

Nevro today announced that it received two patents for its Senza High-Frequency Spinal Cord Stimulation System, a device aimed at patients with chronic pain. The first patent concerns the device’s ...

Nevro Corp. retained advisors to explore strategic alternatives, including a possible sale of the business or acquisitions that could shift its focus to earlier points in the pain management process.